Evidence map›Paper›PMID 40971637›Full record

ArticleDiabetes care2025

Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV.

Andrew W Hahn, S A Ruderman, R M Nance, B M Whitney, S Eltonsy, L Haidar, L N Drumright, J Ma, K H Mayer, S Napravnik and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Andrew W HahnUniversity of Washington, Seattle, WA.ORCID 0000-0002-9552-1700
S A RudermanUniversity of Washington, Seattle, WA.
R M NanceUniversity of Washington, Seattle, WA.
B M WhitneyUniversity of Washington, Seattle, WA.
S EltonsyUniversity of Manitoba, Winnipeg, Manitoba, CA.
L HaidarUniversity of Manitoba, Winnipeg, Manitoba, CA.
L N DrumrightUniversity of Washington, Seattle, WA.
J MaUniversity of Washington, Seattle, WA.
K H MayerThe Fenway Institute, Harvard Medical School, Boston, MA.
S NapravnikUniversity of North Carolina, Chapel Hill, NC.
J J EronUniversity of North Carolina, Chapel Hill, NC.
K A ChristopoulosUniversity of California San Francisco, San Francisco, CA.
L BamfordUniversity of California San Diego, La Jolla, CA.
E R CachayUniversity of California San Diego, La Jolla, CA.
G YendewaCase Western University, Cleveland, OH.
A PettitVanderbilt University, Nashville, TN.
M S SaagUniversity of Alabama at Birmingham, Birmingham, AL.
S L HeathUniversity of Alabama at Birmingham, Birmingham, AL.
R D MooreJohns Hopkins University, Baltimore, MD.
J C KerulyJohns Hopkins University, Baltimore, MD.
D S BateyTulane University, New Orleans, LA.
G ChanderUniversity of Washington, Seattle, WA.
M M KitahataUniversity of Washington, Seattle, WA.
J A C DelaneyUniversity of Washington, Seattle, WA.
H M CraneUniversity of Washington, Seattle, WA.
R J FredericksenUniversity of Washington, Seattle, WA.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
Substance use patterns and contexts: impact on epigenetic age and prevention strategies in an HIV clinical care cohortR01DA047045 · NIDA · UNIVERSITY OF WASHINGTON · PI Heidi M. Crane, Joseph Austin Delaney · 2018 to 2026
$5.1M
Links between Cardiovascular disease, Lung disease, and Obstructive sleep apnea in HIV: Understanding complex patientsR01HL126538 · NHLBI · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., CROTHERS, KRISTINA ANNE · 2015 to 2025
$5.1M
Understanding Health Inequities at the Intersection of the HIV and substance use epidemics across racial/ethnic and other underserved populationsR01DA058938 · NIDA · UNIVERSITY OF WASHINGTON · PI Heidi M. Crane, Rob Fredericksen · 2023 to 2026
$2.8M
National Institute of Allergy and Infectious Diseases UAB CFAR Grant P30 AI027767National Institute of Allergy and Infectious Diseases UNC CFAR Grant P30 AI50410National Institute of Allergy and Infectious Diseases UW CFAR NIAID Grant P30 AI027757NHLBI NIH HHS R01 HL126538NHLBI NIH HHS R01HL126538NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI110527NIAID NIH HHS R24 AI067039NIDA NIH HHS R01 DA047045NIDA NIH HHS R01DA047045NIDA NIH HHS R01 DA058938NIDA NIH HHS R01DA058938
6 · The paper itself

Abstract

objectiveTo evaluate semaglutide use among people with HIV (PWH) with medical indications by race and ethnicity. RESEARCH DESIGN AND

methodsWe identified PWH in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort at nine sites eligible for semaglutide therapy between 2019 and 2023. Semaglutide eligibility was based on BMI ≥30 or HbA1c ≥6.5. We evaluated differences in semaglutide receipt among eligible PWH by race and ethnicity using relative risk regression adjusted for demographic characteristics.

resultsAmong 11,617 eligible PWH, 774 (6.7%) received semaglutide (92% eligible by BMI ≥30, 62% by HbA1c ≥6.5, and 54% by both criteria). Eligible Black PWH were 20% less likely to receive semaglutide versus White PWH (prevalence ratio [PR] 0.80, 95% CI 0.67-0.95). The lower rate of semaglutide for Black (PR 0.66, 95% CI 0.53-0.83) and Hispanic PWH (PR 0.70, 95% CI 0.53-0.93) was more pronounced among those with higher HbA1c (≥8.0).

conclusionsWe describe inequitable semaglutide use among PWH, with lower initiation rates in eligible Black PWH.

Indexed as

Glucagon-Like PeptidesHealthcare DisparitiesHIV InfectionsHypoglycemic AgentsAdultBlack or African AmericanFemaleGlucagon-Like Peptide 1Glycated HemoglobinHispanic or LatinoHumansMaleMiddle AgedSemaglutideWhiteWhite PeopleGlucagon-Like Peptide 1Glucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsSemaglutide

Identifiers

PMID40971637
PMCPMC12451842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.